Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035
Ascletis Signs an Exclusive License Agreement with Alphamab for its KN035
Shots:
- Alphamab to receive upfront, milestones and royalties on sales of KN035 (ASC22). Ascletis to get exclusive development and commercialization rights for Alphamab’s KN035 (ASC22) in Greater China
- Alphamab will be responsible to manufacture and commercialize ASC22 (KN035) in Greater China and Ascletis to receive economics (Ex-China) from Alphamab on its regulatory approval in China
- KN035 (ASC22) is an anti-PD-L1 mAb, targeted to treat chronic Hepatitis B and viral diseases across the US, China and Japan
Click here to read full press release/ article | Ref: PRNewswire | Image: Select Science